insights_auto
Outlook: 54.5% bullish·0.0% bearish
Go to analysischevron_right
GILD:NASDAQ
Gilead Sciences, Inc
$156.19
arrow_downward
-0.75%(-1.18) 1D
$156.84
arrow_upward
+0.42% (+0.65)bedtimeAfter hours
Closed: Oct 16, 4:00:02 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GILD...
Open
$157.32
High
$157.58
Low
$155.62
Mkt. cap
193.67B
Avg. vol.
5.79M
Volume
7.77M
Dividend
2.10%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$160.51
52-wk low
$114.02
EPS
-$2.66
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
Open
$157.32
High
$157.58
Low
$155.62
Mkt. cap
193.67B
Avg. vol.
5.79M
Volume
7.77M
Dividend
2.10%
Quarterly dividend
$0.82
Ex-dividend date
Sep 15, 2026
52-wk high
$160.51
52-wk low
$114.02
EPS
-$2.66
Beta
0.32
Shares outstanding
1.24B
No. of employees
17K
News stories
From web sources and news partners
MarketBeat
·
2 hours ago
Gilead Sciences (NASDAQ:GILD) CFO Andrew Dickinson Sells 3,000 Shares of Company Stock
Stock Titan
·
3 hours ago
Under a trading plan, Gilead Sciences (GILD) CFO sells 3,000 shares at $156.22 each.
Simply Wall Street
·
14 hours ago
What Could Gilead Sciences (GILD) New Solid Tumor Partnership Mean For Oncology?
Kalkine Media
·
16 hours ago
Could Gilead Sciences (NASDAQ:GILD) Be in Focus After Wall Street’s Latest Rotation?
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
About Gilead Sciences, Inc
CEODaniel O'Day
Employees17K
FoundedJun 22, 1987
HeadquartersFoster City, California, United States
SectorBiotechnology
Websitegilead.com